Total Payments
$280,591
2024 Payments
$32,074
Companies
33
Transactions
192
Medicare Patients
870
Medicare Billing
$228,140
Payment Breakdown by Category
Research$124,186 (44.3%)
Consulting$85,883 (30.6%)
Other$47,936 (17.1%)
Travel$17,215 (6.1%)
Food & Beverage$5,371 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $124,186 | 6 | 44.3% |
| Consulting Fee | $85,883 | 35 | 30.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,911 | 23 | 16.4% |
| Travel and Lodging | $17,215 | 47 | 6.1% |
| Food and Beverage | $5,371 | 80 | 1.9% |
| Honoraria | $2,025 | 1 | 0.7% |
Payments by Type
General
$156,405
186 transactions
Research
$124,186
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $157,291 | 37 | $0 (2024) |
| Lilly USA, LLC | $28,264 | 22 | $0 (2024) |
| Kite Pharma, Inc. | $21,856 | 27 | $0 (2024) |
| Incyte Corporation | $17,950 | 25 | $0 (2024) |
| Celgene Corporation | $16,314 | 13 | $0 (2024) |
| Genentech, Inc. | $6,000 | 2 | $0 (2023) |
| Verastem, Inc. | $4,178 | 3 | $0 (2019) |
| Ipsen Biopharmaceuticals, Inc | $3,480 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $3,340 | 4 | $0 (2024) |
| ABBVIE INC. | $2,708 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,074 | 38 | Lilly USA, LLC ($18,025) |
| 2023 | $40,153 | 55 | Eli Lilly and Company ($15,914) |
| 2022 | $134,920 | 20 | Eli Lilly and Company ($124,825) |
| 2021 | $17,903 | 10 | Eli Lilly and Company ($10,350) |
| 2020 | $14,799 | 9 | Eli Lilly and Company ($6,038) |
| 2019 | $36,875 | 42 | Celgene Corporation ($13,623) |
| 2018 | $2,768 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($1,916) |
| 2017 | $1,101 | 4 | Jazz Pharmaceuticals Inc. ($750.00) |
All Payment Transactions
192 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $498.26 | Research |
| Study: Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $385.46 | Research |
| Study: Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | ||||||
| 12/09/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $143.94 | General |
| 12/08/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $31.93 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $391.86 | Research |
| Study: CYTB323A12101 | ||||||
| 12/06/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $45.48 | General |
| Category: BioOncology | ||||||
| 10/23/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,480.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $771.93 | General |
| 09/30/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.12 | General |
| Category: Hematology/Oncology | ||||||
| 09/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $48.38 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $39.14 | General |
| Category: BioOncology | ||||||
| 09/05/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $59.85 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $29.90 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Eli Lilly and Company | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $32.00 | General |
| Category: Oncology | ||||||
| 08/07/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.56 | General |
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 07/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $6.44 | General |
| 06/02/2024 | Genmab U.S., Inc. | — | Food and Beverage | In-kind items and services | $49.97 | General |
| 06/01/2024 | Eli Lilly and Company | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $132.26 | General |
| Category: Oncology | ||||||
| 04/28/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.51 | General |
| 04/09/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 04/05/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $438.64 | General |
| Category: Oncology | ||||||
| 04/05/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $109.88 | General |
| Category: Oncology | ||||||
| 04/05/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $84.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | Eli Lilly and Company | $111,310 | 1 |
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | Eli Lilly and Company | $11,600 | 2 |
| Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | F. Hoffmann-La Roche AG | $883.72 | 2 |
| CYTB323A12101 | Novartis Pharmaceuticals Corporation | $391.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 217 | 473 | $210,402 | $38,794 |
| 2022 | 5 | 220 | 632 | $287,677 | $57,801 |
| 2021 | 7 | 248 | 687 | $313,967 | $74,494 |
| 2020 | 5 | 185 | 607 | $287,647 | $57,052 |
Total Patients
870
Total Services
2,399
Medicare Billing
$228,140
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 58 | 187 | $103,411 | $19,389 | 18.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 72 | 136 | $48,270 | $8,887 | 18.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 47 | $22,936 | $4,208 | 18.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 42 | $14,070 | $2,499 | 17.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 42 | 47 | $11,327 | $1,960 | 17.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $10,388 | $1,850 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 60 | 259 | $139,585 | $27,322 | 19.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 135 | $63,990 | $10,403 | 16.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 16 | 63 | $29,610 | $10,051 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 71 | 122 | $42,090 | $8,090 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 40 | 53 | $12,402 | $1,935 | 15.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 70 | 249 | $129,729 | $27,262 | 21.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 31 | 159 | $72,504 | $25,548 | 35.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 62 | 108 | $36,180 | $8,026 | 22.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 95 | $43,700 | $7,502 | 17.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $11,883 | $2,375 | 20.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 13 | $9,529 | $1,989 | 20.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 32 | 46 | $10,442 | $1,791 | 17.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 83 | 326 | $165,430 | $27,490 | 16.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 18 | 92 | $40,756 | $14,633 | 35.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 112 | $50,064 | $9,145 | 18.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 42 | 59 | $19,175 | $3,540 | 18.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $12,222 | $2,245 | 18.4% |
About Dr. Nirav Shah, MD
Dr. Nirav Shah, MD is a Internal Medicine healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2008. The National Provider Identifier (NPI) number assigned to this provider is 1245491257.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nirav Shah, MD has received a total of $280,591 in payments from pharmaceutical and medical device companies, with $32,074 received in 2024. These payments were reported across 192 transactions from 33 companies. The most common payment nature is "" ($124,186).
As a Medicare-enrolled provider, Shah has provided services to 870 Medicare beneficiaries, totaling 2,399 services with total Medicare billing of $228,140. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Milwaukee, WI
- Active Since 06/23/2008
- Last Updated 10/01/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1245491257
Products in Payments
- JAYPIRCA (Drug) $9,309
- JAKAFI (Drug) $8,028
- Tecartus (Drug) $5,946
- MONJUVI (Drug) $5,309
- Copiktra (Drug) $4,178
- Tazverik (Drug) $3,480
- JCAR017 (Drug) $3,164
- Polivy (Biological) $3,085
- ADCETRIS (Biological) $2,475
- KYMRIAH (Biological) $2,061
- CALQUENCE (Drug) $2,055
- BB-2121 (Drug) $2,025
- TAZVERIK (Drug) $2,025
- UKONIQ (Drug) $2,025
- Entyvio (Biological) $1,916
- VENCLEXTA (Drug) $1,848
- IMBRUVICA (Drug) $1,534
- EPKINLY (Drug) $859.85
- Defitelio (Drug) $750.00
- BRUKINSA (Drug) $291.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Milwaukee
Dr. Jeremiah Depta, M.d, M.D
Internal Medicine — Payments: $686,844
Internal Medicine $686,844
Dr. Binod Dhakal, Md, MD
Internal Medicine — Payments: $605,281
Internal Medicine $605,281
Dr. Lee Biblo, Md, MD
Internal Medicine — Payments: $382,388
Internal Medicine $382,388
Dr. Daniel Stein, M.d, M.D
Internal Medicine — Payments: $348,496
Internal Medicine $348,496
Gilbert Jenouri, M.d, M.D
Internal Medicine — Payments: $229,172
Internal Medicine $229,172
Dr. Erik Stilp, Md, MD
Internal Medicine — Payments: $168,213
Internal Medicine $168,213